JUBLPHARMA - IntraDay Trade Analysis with Live Signals
Back to ListIntraDay Trade Rating: 3.3
| Stock Code | JUBLPHARMA | Market Cap | 13,580 Cr. | Current Price | 851 ₹ | High / Low | 1,250 ₹ |
| Book Value | 141 ₹ | Dividend Yield | 0.58 % | ROCE | 2.91 % | ROE | 1.04 % |
| Face Value | 1.00 ₹ | DMA 50 | 916 ₹ | DMA 200 | 1,009 ₹ | Chg in FII Hold | -0.60 % |
| Chg in DII Hold | 0.70 % | PAT Qtr | 6.60 Cr. | PAT Prev Qtr | -48.0 Cr. | RSI | 45.4 |
| MACD | -26.8 | Volume | 84,305 | Avg Vol 1Wk | 1,81,761 | Low price | 784 ₹ |
| High price | 1,250 ₹ | Debt to equity | 0.02 | 52w Index | 14.4 % | Qtr Profit Var | 154 % |
| EPS | 1.23 ₹ | Industry PE | 27.6 |
📊 Analysis: JUBLPHARMA shows weak intraday momentum with RSI at 45.4 (neutral to weak) and MACD at -26.8 (bearish). Price is trading below both 50 DMA (916 ₹) and 200 DMA (1,009 ₹), indicating short-term weakness. Volume is below average, reducing conviction. Fundamentals are weak (ROE 1.04%, ROCE 2.91%), with very low EPS (1.23 ₹). PAT improved (6.60 Cr vs -48.0 Cr), but overall profitability remains fragile. Debt-to-equity at 0.02 is low, which supports financial stability despite weak returns.
💰 Optimal Buy Price: 845–855 ₹ (near support, above 784 ₹ low).
🎯 Profit Exit Levels: 870 ₹ (first resistance), 890 ₹ (second resistance).
🛡️ Stop-Loss: 835 ₹ (below intraday support).
📈 If Already Holding: Exit near 870–890 ₹ if momentum indicators show reversal with strong volume. If price fails to sustain above 845 ₹, consider exiting to protect capital.
✅ Positive
- PAT improved (6.60 Cr vs -48.0 Cr)
- DII holding increased (+0.70%)
- Dividend yield at 0.58% provides minor income support
- Debt-to-equity ratio at 0.02 (very low leverage)
⚠️ Limitation
- RSI at 45.4 shows weak momentum
- MACD negative, bearish trend
- Trading below 50 DMA and 200 DMA
- Volume below average
- ROE (1.04%) and ROCE (2.91%) are very weak
📉 Company Negative News
- PAT remains low despite improvement
- FII holding decreased (-0.60%)
- EPS at 1.23 ₹, weak earnings
📈 Company Positive News
- PAT recovery from losses in previous quarter
- DII holding increased (+0.70%)
- Dividend yield at 0.58% adds investor confidence
🏭 Industry
- Industry PE at 27.6 vs JUBLPHARMA’s weak earnings (no meaningful P/E)
- Pharma sector showing steady demand but margin pressures remain
🔎 Conclusion
JUBLPHARMA is showing weak technical signals and fragile fundamentals despite PAT recovery. Suitable only for cautious intraday trades near support with strict stop-loss. Best for short scalps today rather than aggressive intraday positions.
Would you like me to extend this into a peer benchmarking overlay (Sun Pharma, Divi’s Labs, Dr. Reddy’s) so you can compare JUBLPHARMA’s intraday setup against sector leaders for confirmation signals?